Detalhe da pesquisa
1.
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants.
J Allergy Clin Immunol
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38763170
2.
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Ann Rheum Dis
; 83(1): 30-47, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36927642
3.
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
Rheumatology (Oxford)
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775637
4.
Differences in IgG autoantibody Fab glycosylation across autoimmune diseases.
J Allergy Clin Immunol
; 151(6): 1646-1654, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36716825
5.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
N Engl J Med
; 383(12): 1117-1128, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32937045
6.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
J Autoimmun
; 135: 102984, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621174
7.
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
BMC Infect Dis
; 23(1): 332, 2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37198536
8.
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Kidney Int
; 101(2): 403-413, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34560137
9.
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet
; 397(10289): 2070-2080, 2021 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971155
10.
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
BMC Med
; 20(1): 100, 2022 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236350
11.
Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism.
Transpl Int
; 35: 10269, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35651879
12.
The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture.
Transpl Int
; 35: 10369, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35812159
13.
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
Nephrol Dial Transplant
; 36(8): 1474-1483, 2021 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32591783
14.
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Ann Rheum Dis
; 79(6): 713-723, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32220834
15.
A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE.
Rheumatology (Oxford)
; 59(10): 2734-2745, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31951278
16.
Telemonitoring for Patients With COVID-19: Recommendations for Design and Implementation.
J Med Internet Res
; 22(9): e20953, 2020 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32833660
17.
Immunoengineering for autoimmune-kidney disease.
Nephrol Dial Transplant
; 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38889934
18.
Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits.
Kidney Int
; 93(1): 214-220, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950993
19.
Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA.
Kidney Int
; 94(1): 139-149, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29606398
20.
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.
Ann Rheum Dis
; 82(6): 883-885, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720583